Vircell Highlights All-in-One CLIA System and Real Time PCR Kits
|
By LabMedica International staff writers Posted on 13 Nov 2023 |

Vircell (Granada, Spain) is highlighting the VirClia LOTUS CLIA analyzer at MEDICA 2023, the world's largest event for the medical sector. The VirClia LOTUS fully automated random access and continuous loading CLIA analyzer marks a revolution in infectious serology by offering the benefit of any test, any sample, any time. The analyzer allows to run more than 90 infectious markers in a monotest format with total flexibility and no need for reagents on board. The first results are available within 70 minutes and then, every 35 seconds thereafter.
VirClia Lotus accepts any combination of samples and reagents, regardless of the instrument status. Even while running, it remains accessible for reagent and sample addition. Urgent samples can be prioritized. With VirClia Lotus, STAT test requests are given the highest priority for processing. This true monotest solution allows the laboratory to run esoteric and low-volume infectious serology tests daily, alongside the laboratory routine. VirClia Lotus unifies in just one CLIA system, all those parameters are typically performed with ELISA, IFA, or Rapid Tests.
The instrument’s built-in scanner allows for full traceability of both samples and strips, avoiding clerical errors. Labs can save hands-on time using primary tubes (11-16 mm) directly in VirClia Lotus, avoiding the inconvenience of transferring samples or performing external predilution. VirClia Lotus offers the widest panel for infectious serology in CLIA, continuous loading, and multi-batch testing to run any number of different VirClia parameters simultaneously.
Related Links:
Vircell
Latest Medica 2023 News
- Absology Showcases Latest Advancements in Medical Diagnostics
- Noul Showcases AI-Driven Blood and Cancer Diagnostic Platform
- Oruba Presents State-of-the-Art Self-Operating Uroflowmeters
- Awareness Technology Exhibits Incredibly Flexible ChemWell 2 ELISA and Chemiluminescent Analyzer
- BioVendor Group Demonstrates Unique IVD Platform and Immunoblot Test
- Greiner Bio-One Highlights Magnetic 3D Cell Culture Technology
- Fujirebio Showcases Range of Novel Testing Solutions
- Sentinel Diagnostics Demonstrates New SENTiNAT 200 and STAT-NAT Kits for Infectious Diseases
- DiaSys Showcases High Quality Diagnostic Reagents and System Solutions
- Randox Exhibits Full Range of Molecular Diagnostic Solutions
- Alcor Scientific Demonstrates Fully-Automated ESR Analyzers
- Bosch Healthcare Presents Vivalytic Point-of-Care PCR System
- CerTest Presents Innovations Related to VIASURE Products
- Tianlong Showcases Cutting-Edge Products and Innovative Molecular Diagnostic Solutions
- Getein Biotech Exhibits Advanced POCT Analyzers
- LumiraDx Demonstrates Transformative Tests and Technologies
Channels
Clinical Chemistry
view channelNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read more
Blood Metabolite Test Detects Early Cognitive Decline
Timely identification of individuals at risk of dementia remains difficult because symptoms commonly appear only after significant neurodegeneration. Accessible screening tools that flag subtle cognitive... Read moreMolecular Diagnostics
view channel
Noninvasive Urine Test Predicts Recurrence After BCG in Bladder Cancer
Bladder cancer is among the most common malignancies in the United States and frequently recurs even when diagnosed at the non‑muscle invasive stage (NMIBC). After transurethral resection, many patients... Read more
Mesothelioma in Younger Adults Linked to Genetic Risk Factors
Mesothelioma is a rare malignancy of the pleura, historically linked to occupational asbestos exposure and most often diagnosed in older men. About 3,300 people are diagnosed each year in the United States,... Read moreHematology
view channel
Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
Blood cancers encompass diverse entities whose biology and clinical behavior are best understood through integrative analyses across large cohorts. However, multi‑omic datasets and outcomes information... Read more
AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
Bone marrow aspirate examination is central to diagnosing and monitoring blood cancers and other serious hematologic diseases, yet the process in many laboratories remains manual and highly dependent on... Read moreImmunology
view channelCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
Intensive care units face persistent threats from hospital-acquired infections, increasingly driven by drug-resistant bacteria. Rapidly pinpointing environmental reservoirs and transmission hotspots remains... Read more
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read morePathology
view channel
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read moreTechnology
view channel
Noninvasive Sputum Test Detects Early Lung Cancer
Early detection remains critical for improving outcomes in lung cancer, yet clinicians increasingly encounter indeterminate pulmonary nodules found incidentally or through screening, complicating decision-making.... Read more
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
GRAIL Partners with Epic to Integrate Multi-Cancer Test into EHR
GRAIL’s Galleri multi-cancer early detection (MCED) test is being integrated into Epic’s electronic health record (EHR) platform through Epic Aura. The collaboration is designed to let clinicians at interested... Read moreGlobal Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more








